{"schema_version":"1.0","type":"article","title":"投資人請注意，自體免疫超大藥賽道","url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.md","lang":"zh-Hant","date":"2026-04-14","publish_at":"2026-04-14T10:30:00+08:00","updated_at":"2026-04-14","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"自體免疫藥物市場，從來都不是「穩定但無聊」的成熟市場。恰恰相反，它一直是全球最容易長出重磅藥物的沃土之一，而乾癬（psoriasis），正是這條價值鏈裡最具代表性的試驗場。","key_points":[],"facts":[],"sections":["自體免疫超大藥賽道全面升級：從乾癬紅海到 IBD 雙路徑革命","乾癬這條線，本來就是一部治療升級史","第一個升級方向：把高效機轉做得更方便、更早線","第二個升級案例：不是新標靶，而是更強的同路徑差異化","第二個真正的大升級：IBD 進入雙路徑時代","VEGA 試驗真正證明了什麼？","這不只是 JNJ 的故事，整個產業都開始跟進","自體免疫超大藥賽道，真的進入了新週期","寫在最後"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results - Feb 4, 2026","source":"","date":"","url":""},{"title":"Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76...","source":"","date":"","url":""},{"title":"news.abbvie.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Psoriasis is a debilitating inflammatory condition that affects physiological and psychological states of millions around the world. Conventional biologic and nonbiologic therapies are fraught with profound adverse side effect profiles, frequent ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Bristol Myers Squibb - U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis","source":"","date":"","url":""},{"title":"Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10","source":"","date":"","url":""},{"title":"news.bms.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide","source":"","date":"","url":""},{"title":"Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoria","source":"","date":"","url":""},{"title":"www.jnj.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"www.ucb.com","source":"","date":"","url":""},{"title":"https://www.ucb.com/sites/default/files/press_files/80f57daf1260cff4.pdf","source":"","date":"","url":"https://www.ucb.com/sites/default/files/press_files/80f57daf1260cff4.pdf"},{"title":"www.ucb.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-01.webp"},{"alt":"Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-02.webp"},{"alt":"Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-14）。投資人請注意，自體免疫超大藥賽道。https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-14-dcard-261295358-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}